Rigel Pharmaceuticals to Showcase Innovative Pipeline at Upcoming Healthcare Conference

Rigel Pharmaceuticals Set to Present at Healthcare Conference, Highlighting Commitment to Innovation

Rigel Pharmaceuticals, Inc., a leading biotechnology company based in South San Francisco, announces that Dean Schorno, its Chief Financial Officer, will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 8:30 am ET. This presentation aims to provide insights into Rigel's innovative pipeline and the company's ongoing commitment to developing new therapies for patients suffering from hematologic disorders and cancer. Given the growing demand for effective treatments in these critical areas, Rigel's participation in the conference serves as a strategic opportunity to engage with the investment community and showcase its advancements.

Founded in 1996, Rigel Pharmaceuticals has built a reputation for its focus on hematologic and oncological therapies. The company's dedication to improving patient outcomes is evident in its robust pipeline, which includes both novel drug candidates and marketed products. By participating in industry conferences like the Piper Sandler event, Rigel aims to not only share its progress but also to gather feedback from potential investors and stakeholders. This proactive approach underscores the company's mission to enhance the lives of patients through innovative therapeutic solutions and to position itself as a leader in the biotechnology sector.

The live webcast of the presentation will be accessible through the Investor Relations section of Rigel's website, where interested parties are encouraged to connect in advance to ensure a smooth experience. This accessibility reflects Rigel's commitment to transparency and open communication with its stakeholders. For further inquiries, investors can reach Rigel Pharmaceuticals directly, while media inquiries can be directed to David Rosen of Argot Partners. Overall, the upcoming presentation at the Piper Sandler Healthcare Conference illustrates Rigel Pharmaceuticals' steadfast dedication to advancing treatment options in hematology and oncology, reaffirming its position as a key player in the biotechnology landscape.

In addition to the conference announcement, Rigel Pharmaceuticals remains focused on expanding its portfolio and enhancing its research capabilities. The ongoing development of its therapies aligns with the increasing need for novel treatments in the face of rising incidences of hematologic disorders and various cancers. As the company continues to innovate, the advancements it makes will be critical not only for its growth but also for improving patient care in these challenging areas.

As Rigel Pharmaceuticals prepares for its upcoming presentation, it highlights the importance of investor engagement in driving the company's mission forward. The commitment to developing groundbreaking therapies positions Rigel as a forward-thinking entity in the biotechnology industry, dedicated to making a significant impact on patient health and wellness.